Utility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?

@article{Desai2018UtilityOP,
  title={Utility of para-aminosalicylic acid in drug-resistant tuberculosis: Should it be classified as Group D3 or Group C?},
  author={U. Desai and J. Joshi},
  journal={Lung India : Official Organ of Indian Chest Society},
  year={2018},
  volume={35},
  pages={488 - 493}
}
  • U. Desai, J. Joshi
  • Published 2018
  • Medicine
  • Lung India : Official Organ of Indian Chest Society
Background: The World Health Organization drug-resistant tuberculosis (DR-TB) 2016 guidelines reclassified para-aminosalicylic acid (PAS) as Group D3 “add-on” drug. We studied our DR-TB data wherein PAS was widely and preferably used as a substitute in the standardized regimen in varied situations and report its utility in DR-TB. Methodology: This retrospective observational study enrolled both pulmonary and extrapulmonary DR-TB patients receiving PAS in the programmatic management of DR-TB… Expand
3 Citations

References

SHOWING 1-10 OF 23 REFERENCES
Para-aminosalicylic acid: the return of an old friend.
Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
French Nationwide Cohort Temporary Utilization Authorization Survey of GranuPAS® in MDR-TB Patients
Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India.
  • D. Agrawal, Z. Udwadia, C. Rodríguez, A. Mehta
  • Medicine
  • The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • 2009
Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis.
  • Medicine
  • The American review of respiratory disease
  • 1979
...
1
2
3
...